- Previous Close
153.40 - Open
153.40 - Bid 152.80 x --
- Ask 153.00 x --
- Day's Range
152.20 - 154.50 - 52 Week Range
98.50 - 185.60 - Volume
70,528 - Avg. Volume
169,746 - Market Cap (intraday)
33.828B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
43.66 - EPS (TTM)
3.50 - Earnings Date Feb 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 16, 2017
- 1y Target Est
179.20
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
www.alk.netRecent News: ALK-B.CO
View MorePerformance Overview: ALK-B.CO
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALK-B.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALK-B.CO
View MoreValuation Measures
Market Cap
33.96B
Enterprise Value
33.91B
Trailing P/E
43.83
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.44
Price/Book (mrq)
6.68
Enterprise Value/Revenue
6.30
Enterprise Value/EBITDA
25.27
Financial Highlights
Profitability and Income Statement
Profit Margin
13.32%
Return on Assets (ttm)
8.54%
Return on Equity (ttm)
15.16%
Revenue (ttm)
5.18B
Net Income Avi to Common (ttm)
690M
Diluted EPS (ttm)
3.50
Balance Sheet and Cash Flow
Total Cash (mrq)
420M
Total Debt/Equity (mrq)
10.31%
Levered Free Cash Flow (ttm)
483.12M